Quick Answer
Pasithea Therapeutics Corp. reported Net Income of -$20.43 million for fiscal year 2025.
Pasithea Therapeutics Corp. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$20.43M | -46.9% |
| 2024 | -$13.90M | +12.9% |
| 2023 | -$15.96M | -14.5% |
| 2022 | -$13.94M | -541.2% |
| 2021 | -$2.17M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.04M | -1.3% | +18.3% |
| June 30, 2025 | -$3.72M | +3.9% | -4.3% |
| March 31, 2025 | -$3.56M | +7.7% | -18.8% |
| September 30, 2024 | -$3.00M | +17.0% | +22.4% |
| June 30, 2024 | -$3.87M | -2.7% | -0.1% |
| March 31, 2024 | -$3.86M | -9.1% | -6.9% |
| September 30, 2023 | -$3.61M | +21.2% | +4.0% |
| June 30, 2023 | -$3.76M | -41.6% | -6.4% |
- Pasithea Therapeutics Corp. showed a decrease of -46.9% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Pasithea Therapeutics Corp.’s net income has declined by 839.8% (from -$2.17 million to -$20.43 million).
- The most recent figure is from Pasithea Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: